What question did this study set out to answer?

To evaluate the effectiveness of alemtuzumab in maintaining NEDA-3 status in patients with RRMS over four years.

February 8, 2026Open Access

Translated article Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

To evaluate the effectiveness of alemtuzumab in maintaining NEDA-3 status in patients with RRMS over four years.
Annual follow-up of patients treated with alemtuzumab
Assessment of NEDA-3 parameters
Longitudinal data analysis over 4 years
Alemtuzumab showed consistent effectiveness across various NEDA-3 metrics
Sustained remission was observed in the treatment cohort
Positive outcomes in clinical practice support previous clinical trial findings

Abstract

Alemtuzumab has proven to be effective, over 4 years, in clinical practice in patients with RRMS according to the different parameters of the NEDA-3 concept.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Translated article Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

Abstract

Cite This Study

Also Consider

Also Consider

Translated article Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

Abstract

Cite This Study

Also Consider

Also Consider

Translated article Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years